TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11343045
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to budesonide 200 microg twice daily
Study: 9633737
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 10 mg every 12 hours, increased weekly up to a maximum of 30 mg every 12 hours
Study: 3348138
Drug: Isosorbide‐5‐mononitrate 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate 10 mg
Study: 3348138
Drug: Isosorbide‐5‐mononitrate 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate 20 mg
Study: 3348138
Drug: Isosorbide‐5‐mononitrate 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate 50 mg
Study: 30269642
Drug: Solriamfetol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 600 mg
Study: 30269642
Drug: Solriamfetol 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 1200 mg
Study: 24743717
Drug: Intramuscular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular olanzapine 10 mg/d
Study: 24743717
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 7.5 mg/d
Study: 22549239
Drug: Ciprocare®XR 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprocare®XR 1000 mg ciprofloxacin (test formulation)
Study: 22549239
Drug: Cipro®XR sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipro®XR sustained release tablet (reference formulation)
Study: 20927040
Drug: Ultrafiltration rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration rates over 13 ml/h/kg
Study: 20927040
Drug: Ultrafiltration rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration rates between 10-13 ml/h/kg
Study: 20927040
Drug: Ultrafiltration rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration rates up to 10 ml/h/kg
Study: 10825337
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg oral dose 90 min before surgery
Study: 1725027
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of ramipril
Study: 1725027
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of ramipril
Study: 6440793
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 30 mg (2 tablets)
Study: 31027098
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with methylene blue (MB) at 0.005% concentration and low intensity laser irradiation (λ = 660 nm, 9J per point, radiant exposure of 318 J/cm)
Study: 26864411
Drug: Dose-equivalent occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-equivalent occupational therapy (DEUCC)
Study: 26864411
Drug: Monitoring-only occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring-only occupational therapy (UCC)
Study: 24499460
Drug: Respiratory therapy
Normalized name: respiratory therapy supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory therapy (Control)
Study: 18443390
Drug: Parent-child cognitive
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-child cognitive behavioral therapy (CBT)
Study: 16110025
Drug: DCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5)
Study: 16110025
Drug: DC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1)
Study: 9649697
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 10 minutes
Study: 9649697
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 20 minutes
Study: 8834128
Drug: Chronic home
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic home oxygen therapy (mean 16.4 h/day) with standard pharmacological treatment (prednisone 10‐15 mg/day) for 4 years
Study: 8834128
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment (prednisone 10‐15 mg/day) alone for 4 years
Study: 2473061
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy and RT with cytokines
Study: 31121331
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of a mixture of 0.5ml hyaluronic acid and 0.5ml corticosteroid
Study: 31121331
Drug: Arthrocentesis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis with Ringer solution
Study: 23378346
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid (prednisolone) administered daily for 3 consecutive days
Study: 23378346
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution) administered daily for 3 consecutive days
Study: 23378346
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid (prednisolone)
Study: 16808624
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (internal dose median 168 mSv, external dose median 280 mSv)
Study: 16808624
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (internal dose negligible, external dose median 22 mSv)
Study: 16808624
Drug: High-dose group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group, Low-dose group, Control group
Study: 15526507
Drug: Rovamycine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovamycine 12 days 4.5 MUI iv/day as add-on therapy
Study: 15526507
Drug: Rovamycine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovamycine 12 days 4.5 MUI iv/day followed by 6 MUI/day per os for another 12 days add-on treatment
Study: 6699425
Drug: Topical 8-methoxypsoralen
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 8-methoxypsoralen (8-MOP) with small doses of UVA irradiation
Study: 31791376
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line antihypertensive treatment
Study: 27222759
Drug: Passive-active distraction
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive-active distraction (combination of both techniques)
Study: 21384431
Drug: Memantine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine treatment in mild AD patients
Study: 21384431
Drug: Memantine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine treatment in moderate AD patients
Study: 17851346
Drug: Rectal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal irrigation
Study: 1693065
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine pranobex (3 g/day)
Study: 30922128
Drug: Early inhaled
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early inhaled bronchodilators
Study: 30922128
Drug: No bronchodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bronchodilators
Study: 23615131
Drug: PEG IFNα‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG IFNα‐2a (135 μg once weekly) plus lamivudine (100 mg daily)
Study: 23615131
Drug: PEG IFNα‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG IFNα‐2a (135 μg once weekly) plus adefovir (10 mg daily)
Study: 17685744
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus ziprasidone 80 mg/day
Study: 17685744
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus ziprasidone 160 mg/day
Study: 15164103
Drug: Nutrient supplementation
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient supplementation containing omega-3 fatty acids (1.4 g EPA, 0.211 g DHA, 0.5 g GLA) and micronutrients
Study: 11477493
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.15 IU/kg body weight/week)
Study: 2956040
Drug: semisynthetic human
Normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: semisynthetic human NPH insulin
Study: 2956040
Drug: porcine NPH
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: porcine NPH insulin
Study: 12601301
Drug: Gemcitabine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (300 mg/m2), Paclitaxel (70 mg/m2), Carboplatin (AUC 5)
Study: 11713946
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg daily (LAN 15)
Study: 11713946
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily (LAN 30)
Study: 11713946
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice a day (RAN 150)
Study: 9165379
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg/daily)
Study: 9165379
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 mg/daily)
Study: 7705093
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to 150 mg + misoprostol 600 micrograms (Group 1)
Study: 7705093
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to 150 mg + PG05 1 mg vaginal suppository (Group 2)
Study: 7712903
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg + misoprostol 600 micrograms (Group 3)
Study: 30439866
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib (IVPA group)
Study: 28189475
Drug: Alprostadil treatment
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil treatment twice daily for 4 weeks
Study: 28189475
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment twice daily for 4 weeks
Study: 25183687
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg once daily) plus Indacaterol (150 μg once daily)
Study: 25183687
Drug: Advair(®) (50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advair(®) (50/250 μg twice daily)
Study: 23212243
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (rt‐PA) for the treatment of acute stroke
Study: 21255498
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) oxygen therapy
Study: 21255498
Drug: Standard high-flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-flow face mask (HFFM) oxygen therapy
Study: 9167811
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (rest and gradual return to activity)
Study: 30251100
Drug: Meniscal repair
Normalized name: Sus scrofa meniscus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meniscal repair concurrent with ACL reconstruction
Study: 28264824
Drug: Supervised 1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised 1-hour aerobic and resistance exercise (twice per week for 18 weeks)
Study: 21693037
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) + Norethisterone acetate (2.5 mg/day)
Study: 21693037
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) + Triptorelin (11.25 mg every 3 months)
Study: 14615107
Drug: Diuretics or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics or beta blockers
Study: 10668157
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (50 mg/day)
Study: 10668157
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel progesterone (90 mg/day)
Study: 8684199
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, once daily for 21 days)
Study: 1832883
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid rescue dose of less than 15 mg/m2
Study: 1832883
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid rescue dose of 15 mg/m2 (75 mg/m2)
Study: 7049346
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (Cy) alone
Study: 7049346
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (Cy) + prednisolone (Pred) 100 mg/m2 orally daily for two days
Study: 7049346
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (Cy) alone in small cell carcinoma
Study: 7049346
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (Cy) alone in non-small cell carcinoma
Study: 27505987
Drug: 2 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mmol/L ferrous sulfate
Study: 27505987
Drug: 2 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mmol/L ferrous fumarate
Study: 24999004
Drug: Caffeine (CAF),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF), 3 mg/kg, 45 min prior to PT
Study: 24999004
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB), 0.3 g/kg, 75 min prior to PT
Study: 17558830
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg) infusions every two weeks for six weeks, then every four weeks
Study: 14726934
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (rEpo) administration starting in the first week of life
Study: 30412479
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (UD) for 2 weeks
Study: 28444084
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (35mg capsules, 70mg/day, for 16 weeks)
Study: 28444084
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, twice daily)
Study: 25223231
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) 250 mL (3 times at 12-hr intervals)
Study: 25223231
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 400 mg (12 hr before tilidine administration)
Study: 25223231
Drug: Tilidine 100
Normalized name: tilidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine 100 mg solution p.o.
Study: 21272194
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy prescribed to patients with diabetes
Study: 21272194
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to intensify therapy
Study: 19428005
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (200 microg every 6 hours)
Study: 17160912
Drug: Ruboxistaurin (PKC-β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin (PKC-β isoform-selective inhibitor)
Study: 11037083
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) - six 30 min sessions over 3 months
Study: 8900907
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg four times daily plus ranitidine 300 mg four times daily
Study: 8900907
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily plus ranitidine 300 mg twice daily
Study: 8900907
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg four times daily plus ranitidine 300 mg twice daily
Study: 8900907
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg four times daily plus ranitidine 300 mg four times daily
Study: 1992998
Drug: Intravenous IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IgG (0.4 g/kg, repeated on days +1 and +5)
Study: 6391389
Drug: Antibiotics (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Group A)
Study: 6391389
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Group B)
Study: 30425012
Drug: Therapeutic Touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Touch (4 treatments on 4 consecutive days)
Study: 19581264
Drug: All hormone-treated
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormone-treated subjects
Study: 19581264
Drug: Combined 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 4 thyroid hormone treatment arms
Study: 17095411
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of caffeine (Experiment A)
Study: 17095411
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of caffeine (Experiment B)
Study: 11422089
Drug: Intravenous metamizol
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizol
Study: 14722642
Drug: Intravenous propacetamol
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propacetamol
Study: 2840630
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) during intensive chemotherapy and irradiation
Study: 2840630
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) for severe varicella-zoster virus infections
Study: 2840630
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) for bacterial infections
Study: 29171129
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTTs) at diagnosis
Study: 28302155
Drug: Topical aganirsen
Normalized name: Aganirsen
DrugBank: Aganirsen (DB15369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aganirsen
Study: 14692209
Drug: Gas chromatography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas chromatography (GC) method for detecting volatile sulfur compounds
Study: 9197826
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (ALA) 30%
Study: 9197826
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (ALA) 10%, 20%, or 30%
Study: 9197826
Drug: Vehicle and
Normalized name: Vehicle and emulsifier patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle and light treatment (Control)
Study: 7018846
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral pentaerythritol tetranitrate (PETN)
Study: 28560554
Drug: Continuous postoperative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous postoperative local analgesia with ropivacaine 5 mg/ml
Study: 19699738
Drug: Rectal enemas
Normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enemas in addition to conventional therapy
Study: 17009844
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Vagimid Dragees) 500 mg metronidazole
Study: 17009844
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation 500 mg metronidazole
Study: 12707123
Drug: Pancuronium (0.08-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.08-0.1 mg/kg)
Study: 12707123
Drug: Rocuronium (0.6-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6-0.8 mg/kg)
Study: 2301321
Drug: Treatment diet
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment diet (electrolyte solution then dilute soy formula, dilute cow's milk formula, or undiluted soy formula)
Study: 6951573
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment with comprehensive, assertive and prolonged follow‐up treatment backed by a 24‐hour crisis service.
Study: 31813230
Drug: Kava (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava (120 mg of kavalactones twice/day)